1. Scrip

Pfizer And Sangamo Start Phase III Study For Hemophilia A Gene Therapy

Giroctocogene Fitelparvovec Sustains Factor VIII Levels With No Bleeds

 
• By Kevin Grogan

The move into Phase III for giroctocogene fitelparvovec comes on the heels of BioMarin's surprise setback when the FDA demanded more proof of durability of its rival hemophilia A gene therapy Roctavian.

New York, July 19, 2016: Corporate lettering on the exterior of the Pfizer headquarters in Manhattan.
Pfizer hoping to lead hemophilia A gene therapy field • Source: Shutterstock

A couple of months after BioMarin Pharmaceutical Inc.’s rival drug Roctavian came unstuck with US regulators, Pfizer Inc. and Sangamo Therapeutics, Inc. have moved their investigational gene therapy for hemophilia A into late-stage studies.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Blood and Clotting

More from Therapy Areas